Suppr超能文献

美国国立癌症研究所-中国中医药与癌症合作研究

US National Cancer Institute-China Collaborative Studies on Chinese Medicine and Cancer.

作者信息

Jia Libin, Lin Hongsheng, Oppenheim Joost, Howard O M Zack, Li Jie, Fan Huiting, Zhao Zhizheng, Farrar William, Zhang Ying, Colburn Nancy, Young Matthew R, Li Weidong, Newman David, O'Keefe Barry R, Beutler John, Liu Jikai, Hao Xiaojiang, Yang Xiaosheng, Ji Tengfei, White Jeffrey D

机构信息

Office of Cancer Complementary and Alternative Medicine, Division of Cancer Treatment and Diagnosis, and Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD; Cancer Institute, China Academy of Chinese Medical Sciences, Beijing, China; Laboratory of Molecular Immunoregulation, Laboratory of Cancer Prevention, Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD; Natural Products Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD; Kunming Institute of Botany, China Academy of Sciences, Kunming, China; Key Laboratory of Chemistry for Natural Products in Guizhou Province, China Academy of Sciences, Gui Yang, China; Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing, China.

出版信息

J Natl Cancer Inst Monogr. 2017 Nov 1;2017(52). doi: 10.1093/jncimonographs/lgx007.

Abstract

Since 2007, the US National Cancer Institute (NCI) Office of Cancer Complementary and Alternative Medicine (OCCAM), together with the Cancer Institute of the China Academy of Chinese Medical Sciences (CICACMS), institutes at China Academy of Sciences and Chinese Academy of Medical Sciences, have engaged in collaborations on Chinese medicine (CM) and cancer research. Through these collaborations, CM drugs and compounds have been studied at NCI labs. This paper summarizes the discoveries and progress on these research projects, exploring the aspects of cancer prevention, botanical drug mechanisms of action and component analysis/quality control (QC), and anticancer activity screening. These and other related projects have been presented in various jointly convened workshops and have provided the backdrop for establishing a new organization, the International Consortium for CM and Cancer, to promote international collaborations in this field.

摘要

自2007年以来,美国国立癌症研究所(NCI)的癌症补充与替代医学办公室(OCCAM)与中国中医科学院癌症研究所(CICACMS)、中国科学院和中国医学科学院的各机构开展了中医药与癌症研究方面的合作。通过这些合作,NCI实验室对中药药物和化合物进行了研究。本文总结了这些研究项目的发现和进展,探讨了癌症预防、植物药作用机制及成分分析/质量控制(QC)以及抗癌活性筛选等方面。这些及其他相关项目已在多次联合举办的研讨会上进行了展示,并为成立一个新的组织——中医药与癌症国际联盟提供了背景,以促进该领域的国际合作。

相似文献

1
US National Cancer Institute-China Collaborative Studies on Chinese Medicine and Cancer.
J Natl Cancer Inst Monogr. 2017 Nov 1;2017(52). doi: 10.1093/jncimonographs/lgx007.
2
Proceedings of the Strategy Meeting for the Development of an International Consortium for Chinese Medicine and Cancer.
J Glob Oncol. 2017 Dec;3(6):814-822. doi: 10.1200/JGO.2016.005710. Epub 2016 Oct 28.
3
Cancer complementary and alternative medicine research at the US National Cancer Institute.
Chin J Integr Med. 2012 May;18(5):325-32. doi: 10.1007/s11655-011-0950-5. Epub 2012 Jan 12.
5
Review of the use of botanicals for epilepsy in complementary medical systems--Traditional Chinese Medicine.
Epilepsy Behav. 2015 Nov;52(Pt B):281-9. doi: 10.1016/j.yebeh.2015.04.050. Epub 2015 Jun 6.
6
Major achievements of evidence-based traditional Chinese medicine in treating major diseases.
Biochem Pharmacol. 2017 Sep 1;139:94-104. doi: 10.1016/j.bcp.2017.06.123. Epub 2017 Jun 19.
8
[Research and development on efficacy of Chinese herbal compound].
Zhongguo Zhong Yao Za Zhi. 2016 Mar;41(6):971-975. doi: 10.4268/cjcmm20160601.
9
Saussurea involucrata: A review of the botany, phytochemistry and ethnopharmacology of a rare traditional herbal medicine.
J Ethnopharmacol. 2015 Aug 22;172:44-60. doi: 10.1016/j.jep.2015.06.033. Epub 2015 Jun 23.
10
Future development of global regulations of Chinese herbal products.
J Ethnopharmacol. 2012 Apr 10;140(3):568-86. doi: 10.1016/j.jep.2012.02.029. Epub 2012 Feb 25.

引用本文的文献

2
Functional Regulation of Ginsenosides on Myeloid Immunosuppressive Cells in the Tumor Microenvironment.
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419886655. doi: 10.1177/1534735419886655.

本文引用的文献

1
Proceedings of the Strategy Meeting for the Development of an International Consortium for Chinese Medicine and Cancer.
J Glob Oncol. 2017 Dec;3(6):814-822. doi: 10.1200/JGO.2016.005710. Epub 2016 Oct 28.
2
Cryptotanshinone targets tumor-initiating cells through down-regulation of stemness genes expression.
Oncol Lett. 2016 Jun;11(6):3803-3812. doi: 10.3892/ol.2016.4444. Epub 2016 Apr 15.
3
Discovery and Characterization of a Biologically Active Non-ATP-Competitive p38 MAP Kinase Inhibitor.
J Biomol Screen. 2016 Mar;21(3):277-89. doi: 10.1177/1087057115615518. Epub 2015 Nov 4.
4
Characterization of the metastatic phenotype of a panel of established osteosarcoma cells.
Oncotarget. 2015 Oct 6;6(30):29469-81. doi: 10.18632/oncotarget.5177.
5
Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro.
Mol Cell Biochem. 2015 Aug;406(1-2):63-73. doi: 10.1007/s11010-015-2424-0. Epub 2015 Apr 26.
6
Targeting AMPK for cancer prevention and treatment.
Oncotarget. 2015 Apr 10;6(10):7365-78. doi: 10.18632/oncotarget.3629.
8
Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways.
Cancer Lett. 2014 Dec 28;355(2):232-41. doi: 10.1016/j.canlet.2014.08.037. Epub 2014 Sep 19.
9
Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice.
Mol Carcinog. 2015 Oct;54(10):1096-109. doi: 10.1002/mc.22179. Epub 2014 May 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验